Results 121 to 130 of about 113,104 (262)
Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. [PDF]
Guo T +20 more
europepmc +1 more source
Truncated CD19 as a selection marker for the isolation of stem cell-derived β-cells
Luo Ting Huang +8 more
doaj +1 more source
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source
Dual-target CAR-T cell therapy: latest updates from the 2025 ASH annual meeting. [PDF]
Feng S, Kong R, Xiao L, Zhou X.
europepmc +1 more source
A novel graphene‐based broad‐spectrum infrared (BSIR) device is developed for the noninvasive treatment of ulcerative colitis (UC). BSIR irradiation effectively alleviates colonic inflammation and accelerates mucosal recovery by inducing the systemic relocation of T lymphocytes to the spleen.
Siyu Chen +15 more
wiley +1 more source
Folate receptor beta targeting of tumor-associated macrophages improves lymphoma cell responses to CD19 CAR T cells. [PDF]
Kalander K +6 more
europepmc +1 more source
The multiple hit model of infantile and epileptic spasms: The 2025 update
Abstract Objective Infantile and epileptic spasms syndrome (IESS) is a developmental and epileptic encephalopathy manifesting with epileptic spasms and poor neurodevelopmental outcomes. There is an urgent need for the development of more effective and tolerated therapies.
Aristea S. Galanopoulou +6 more
wiley +1 more source
B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression. [PDF]
Zhang Z +9 more
europepmc +1 more source
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim +22 more
wiley +1 more source

